bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2023,
Volume and Issue:
unknown
Published: Sept. 13, 2023
Abstract
Amyotrophic
Lateral
Sclerosis
(ALS),
like
many
other
neurodegenerative
diseases,
is
highly
heritable,
but
with
only
a
small
fraction
of
cases
explained
by
monogenic
disease
alleles.
To
better
understand
sporadic
ALS,
we
report
epigenomic
profiles,
as
measured
ATAC-seq,
motor
neuron
cultures
derived
from
diverse
group
380
ALS
patients
and
80
healthy
controls.
We
find
that
chromatin
accessibility
heavily
influenced
sex,
the
iPSC
cell
type
origin,
ancestry,
inherent
variance
arising
sequencing.
Once
these
covariates
are
corrected
for,
able
to
identify
robust
ALS-specific
signals
in
data.
Additionally,
ATAC-seq
data
predict
progression
rates
similar
accuracy
methods
based
on
biomarkers
clinical
status.
These
results
suggest
iPSC-derived
neurons
recapitulate
important
disease-relevant
changes.
Biomarker Research,
Journal Year:
2024,
Volume and Issue:
12(1)
Published: Nov. 19, 2024
Abstract
Epilepsy
remains
a
prevalent
chronic
neurological
disease
that
is
featured
by
aberrant,
recurrent
and
hypersynchronous
discharge
of
neurons
poses
great
challenge
to
healthcare
systems.
Although
several
therapeutic
interventions
are
successfully
utilized
for
treating
epilepsy,
they
can
merely
provide
symptom
relief
but
cannot
exert
disease-modifying
effect.
Therefore,
it
urgent
need
explore
other
potential
mechanism
develop
novel
approach
delay
the
epileptic
progression.
Since
approximately
30
years
ago,
histone
deacetylases
(HDACs),
versatile
epigenetic
regulators
responsible
gene
transcription
via
binding
histones
or
non-histone
substrates,
have
grabbed
considerable
attention
in
drug
discovery.
There
also
substantial
evidences
supporting
aberrant
expressions
and/activities
HDAC
isoforms
reported
epilepsy
inhibitors
(HDACi)
been
purposes
this
condition.
However,
specific
mechanisms
underlying
role
HDACs
progression
not
fully
understood.
Herein,
we
reviewed
basic
information
HDACs,
summarized
recent
findings
associated
with
roles
diverse
subunits
discussed
regulatory
which
affected
development
epilepsy.
Additionally,
provided
brief
discussion
on
as
promising
targets
treatment,
serving
valuable
reference
study
clinical
translation
field.
Pharmacological Research,
Journal Year:
2024,
Volume and Issue:
205, P. 107247 - 107247
Published: June 2, 2024
About
80%
of
brain
disorders
have
a
genetic
basis.
The
pathogenesis
most
neurodegenerative
diseases
is
associated
with
myriad
defects,
epigenetic
alterations
(DNA
methylation,
histone/chromatin
remodeling,
miRNA
dysregulation),
and
environmental
factors.
emergence
new
sequencing
technologies
tools
to
study
the
epigenome
has
led
identifying
predictive
biomarkers
for
earlier
diagnosis,
opening
up
possibility
prophylactical
interventions.
As
result,
advances
in
pharmacogenetics
pharmacoepigenomics
now
allow
personalized
treatments
based
on
profile
each
patient
specific
mechanisms
involved.
This
Review
highlights
complexity
variability
responses
pharmacotherapy,
emphasizing
influence
polymorphisms
pharmacokinetics
pharmacodynamics
drugs
used
treat
those
conditions.
We
specifically
discuss
potential
modulatory
effect
several
an
increased
risk
developing
different
diseases.
explore
genomic
analyzing
individual-specific
drug
metabolism
predict
response
clinical
outcomes.
also
provide
insights
into
mechanism
action
under
investigation
their
impact
disease-modifying
pathways.
Finally,
underscores
great
this
field
enhance
effectiveness
safety
through
medicine.
Journal of Neurology Neurosurgery & Psychiatry,
Journal Year:
2023,
Volume and Issue:
94(12), P. 1064 - 1070
Published: March 24, 2023
Background
Biological
ageing
is
one
of
the
principal
risk
factors
for
neurodegenerative
diseases.
It
becoming
increasingly
clear
that
acceleration
DNA
methylation
age,
as
measured
by
epigenetic
clock,
closely
associated
with
many
age-related
Methods
We
searched
PubMed
and
Web
Science
databases
to
identify
eligible
studies
reporting
clocks
in
several
diseases,
including
Alzheimer’s
disease
(AD),
Parkinson’s
(PD),
amyotrophic
lateral
sclerosis
(ALS)
Huntington’s
(HD).
Results
Twenty-three
(12
AD,
4
PD,
5
ALS,
2
HD)
were
included.
systematically
summarised
clinical
utility
11
(based
on
blood
brain
tissues)
assessing
factors,
age
onset,
diagnosis,
progression,
prognosis
pathology
ALS
HD.
also
critically
described
our
current
understandings
these
evidences,
further
discussed
key
challenges,
potential
mechanisms
future
perspectives
Conclusions
Epigenetic
hold
great
Further
research
encouraged
evaluate
promote
application.
PROSPERO
registration
number
CRD42022365233.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(23), P. 12613 - 12613
Published: Nov. 24, 2024
Neurodegenerative
diseases,
such
as
Alzheimer's,
Parkinson's,
ALS,
and
Huntington's,
remain
formidable
challenges
in
medicine,
with
their
relentless
progression
limited
therapeutic
options.
These
diseases
arise
from
a
web
of
molecular
disturbances-misfolded
proteins,
chronic
neuroinflammation,
mitochondrial
dysfunction,
genetic
mutations-that
slowly
dismantle
neuronal
integrity.
Yet,
recent
scientific
breakthroughs
are
opening
new
paths
to
intervene
these
once-intractable
conditions.
This
review
synthesizes
the
latest
insights
into
underlying
dynamics
neurodegeneration,
revealing
how
intertwined
pathways
drive
course
diseases.
With
an
eye
on
most
promising
advances,
we
explore
innovative
therapies
emerging
cutting-edge
research:
nanotechnology-based
drug
delivery
systems
capable
navigating
blood-brain
barrier,
gene-editing
tools
like
CRISPR
designed
correct
harmful
variants,
stem
cell
strategies
that
not
only
replace
lost
neurons
but
foster
neuroprotective
environments.
Pharmacogenomics
is
reshaping
treatment
personalization,
enabling
tailored
align
individual
profiles,
while
diagnostics
biomarkers
ushering
era
early,
precise
disease
detection.
Furthermore,
novel
perspectives
gut-brain
axis
sparking
interest
mounting
evidence
suggests
microbiome
modulation
may
play
role
reducing
neuroinflammatory
responses
linked
neurodegenerative
progression.
Taken
together,
advances
signal
shift
toward
comprehensive,
personalized
approach
could
transform
care.
By
integrating
techniques,
this
offers
forward-looking
perspective
future
where
treatments
aim
just
manage
symptoms
fundamentally
alter
progression,
presenting
renewed
hope
for
improved
patient
outcomes.
Frontiers in Aging Neuroscience,
Journal Year:
2024,
Volume and Issue:
16
Published: Jan. 16, 2024
Background
Currently,
the
prevalence
of
Alzheimer’s
disease
(AD)
is
progressively
rising,
particularly
in
developed
nations.
There
an
escalating
focus
on
onset
and
progression
AD.
A
mounting
body
research
indicates
that
epigenetics
significantly
contributes
to
AD
holds
substantial
promise
as
a
novel
therapeutic
target
for
its
treatment.
Objective
The
objective
this
article
present
areas
interest,
comprehend
contextual
framework
subject
research,
investigate
prospective
direction
future
development.
Methods
ln
Web
Science
Core
Collection
(WOSCC),
we
searched
documents
by
specific
terms
their
corresponding
free
words.
VOSviewer,
CiteSpace
Scimago
Graphica
were
used
perform
statistical
analysis
measurement
metrics
such
number
published
papers,
national
cooperative
networks,
publishing
countries,
institutions,
authors,
co-cited
journals,
keywords,
visualize
networks
related
content
elements.
Results
We
selected
1,530
articles
from
WOSCC
January
2013
June
2023
about
Based
visual
analysis,
could
get
China
United
States
countries
with
most
field.
Bennett
DA
was
contributed
prestigious
scientist.
top
3
cited
journals
Journal
Disease,
Neurobiology
Aging
Molecular
Neurobiology.
According
keywords
frequency
citations,
ncRNAs,
transcription
factor,
genome,
histone
modification,
blood
DNA
methylation,
acetylation,
biomarkers
hot
directions
today.
Conclusion
bibliometric
epigenetic
promising
direction,
had
potential
be
targets.
Cities & Health,
Journal Year:
2024,
Volume and Issue:
8(6), P. 1153 - 1175
Published: April 15, 2024
Global
urbanisation
has
occurred
in
tandem
with
population
ageing,
having
implications
on
human
cognitive
health.
Urban
environmental
factors
such
as
air
pollution
are
known
risk
of
impairment
and
neurodegenerative
disease.
However,
due
to
the
sparse
evidence
base,
biological
pathways
by
which
urban
operate
not
well
understood.
The
aim
this
review
is
explain
how
exploring
epigenome
(i.e.
chemical
modifications
genome
do
change
underlying
gene
sequence)
can
further
our
understanding
these
pathways.
influenced
for
Utilising
complex
epigenetic
analytical
techniques
including
clocks,
Mendelian
randomization
multi-omic
approaches,
it
possible
identify
consequences
biology.
Through
better
modifications,
be
inherited
or
dynamically
response
exposures,
impact
outcomes,
we
work
encourage
development
public
health
policies,
planning
design
policies
reduce
burden
disease
healthier
ageing
older
adult
population.
Nature Communications,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: May 2, 2024
Amyotrophic
Lateral
Sclerosis
(ALS),
like
many
other
neurodegenerative
diseases,
is
highly
heritable,
but
with
only
a
small
fraction
of
cases
explained
by
monogenic
disease
alleles.
To
better
understand
sporadic
ALS,
we
report
epigenomic
profiles,
as
measured
ATAC-seq,
motor
neuron
cultures
derived
from
diverse
group
380
ALS
patients
and
80
healthy
controls.
We
find
that
chromatin
accessibility
heavily
influenced
sex,
the
iPSC
cell
type
origin,
ancestry,
inherent
variance
arising
sequencing.
Once
these
covariates
are
corrected
for,
able
to
identify
ALS-specific
signals
in
data.
Additionally,
ATAC-seq
data
predict
progression
rates
similar
accuracy
methods
based
on
biomarkers
clinical
status.
These
results
suggest
iPSC-derived
neurons
recapitulate
important
disease-relevant
changes.
